John Shymansky, MD
Neurology · Pittsburgh, PANPI 1205832755
Payments from drug & device makers
Across 194 payments — averaging $339.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$48K
- TG Therapeutics, Inc.$14K
- AbbVie$660
- Eisai Inc.$590
- Biogen$276
- Pfizer$204
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$11,79568%
- Travel & lodging$1,0526%
- Food & beverage$4,29225%
- Education$2531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 19 | $48,439 |
| TG Therapeutics, Inc. | 37 | $14,192 |
| AbbVie | 29 | $660 |
| Eisai Inc. | 22 | $590 |
| Biogen | 9 | $276 |
| Pfizer | 14 | $204 |
| Genentech USA, Inc. | 7 | $163 |
| Lundbeck LLC | 6 | $135 |
| Amgen(2 entities) | 7 | $116 |
| Lilly USA, LLC | 5 | $114 |
| Acadia Pharmaceuticals Inc | 4 | $109 |
| EMD Serono, Inc. | 3 | $92 |
| Bristol Myers Squibb | 4 | $87 |
| Vanda Pharmaceuticals Inc. | 3 | $78 |
| Argenx US, Inc. | 3 | $76 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $75 |
| UCB, Inc. | 3 | $56 |
| Genentech, Inc. | 1 | $50 |
| AstraZeneca | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Livanova USA, Inc. | 1 | $30 |
| Novartis | 1 | $28 |
| Johnson & Johnson | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Neurelis, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Sanofi | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,830 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $270 |
| ClopidogrelClopidogrel Bisulfate | 14 | $259 |
Paid to pharmacies, not to this prescriber.
Other neurology in Pittsburgh
- Jan DrappatzPittsburgh$4M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Valerie SuskiPittsburgh$1.7M
- Oscar LopezPittsburgh$1.5M
- Islam ZaydanPittsburgh$976K
- Amber van LaarPittsburgh$760K
- James ValerianoPittsburgh$714K
- Lana ChahinePittsburgh$633K
- Frank LiebermanPittsburgh$511K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.